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Objective: To identify sources of heterogeneity (statistical, methodological, and clinical) in studies eval-
uating non-steroidal anti-inﬂammatory drugs (NSAIDs) vs acetaminophen in patients with knee and hip
osteoarthritis (OA) to elucidate variations in outcomes.
Method: A database search (1966 to January 2010) was made for (randomized) controlled trials ((R)CTs)
comparing NSAIDs vs acetaminophen in knee and hip OA. Extracted data included baseline demographic/
clinical characteristics, outcomes at follow-up, and characteristics of study design. Heterogeneity was
examined with subgroup analyses by exploring changes in effect size and with I2 of Higgins. Pain
measures were expressed as standardized mean differences.
Results: 15 RCTs, including 21 comparisons of NSAIDs and acetaminophen were included. Statistical
heterogeneity was absent (Cochran’s Q-test¼ 14.11; I2¼ 0; P¼ 0.78). Moderate clinical heterogeneity was
found for comparisons which included both hip and knee OA vs knee OA only (I2¼ 51; P¼ 0.09). NSAIDs
seemed slightly more effective than acetaminophen if more patients with hip OA were included.
However, the pooled effect sizes of comparisons with knee OA vs both knee and hip OA are equal. Low
clinical heterogeneity was found for comparisons with low dosage of acetaminophen, normal dosage of
NSAIDs, and moderate pain intensity at baseline. Low methodological heterogeneity was found for
comparisons with a short duration.
Conclusion: Future trials should present the results of hip and knee OA separately, as moderate clinical
heterogeneity was found. There might be differences in effectiveness of NSAIDs vs acetaminophen in
patients with hip vs knee OA. No signiﬁcant methodological and statistical heterogeneity was found in
studies evaluating NSAIDs vs acetaminophen.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Guidelines for the treatment of non-traumatic knee complaints,
recommend acetaminophen as the ﬁrst-choice analgesic in treat-
ing pain due to osteoarthritis (OA)1e4. This recommendation is
based on a review showing a superior effectiveness of acetamin-
ophen compared to placebo in treating pain due to OA5. In
addition, recent reviews reported only small improvements (effect
sizes from 0.2 to 0.37) in pain in favor of non-steroidal anti-
inﬂammatory drugs (NSAIDs) compared to acetaminophen5e8.
However, NSAIDs were consistently associated with substantially
more side effects9,10.S.P.J. Verkleij, Department of
ter Rotterdam, P.O. Box 2040,
2-117; Fax: 31-10-703-2-127.
kleij).
s Research Society International. PSystematic reviews integrate the results of original studies. In
order to pool the data of original studies in a quantitative manner
(meta-analysis), the reviews investigate whether statistical
heterogeneity exists (i.e., when the statistical difference between
studies is larger than expected by chance). If studies are statistically
heterogeneous, there is no added value of pooling while the pooled
effect size might be biased. No statistical heterogeneity was
reported in the four reviews comparing the efﬁcacy of NSAIDs vs
acetaminophen5e8.
There are two other types of heterogeneity. Clinical heteroge-
neity can result from differences in the characteristics of the
included patients, from the interventions applied, and from the use
of different outcome measures. Methodological heterogeneity ari-
ses when different study designs are used, and with differences in
the degree of control over bias11. However, data on clinical and
methodological heterogeneity in systematic reviews are scarce.
A meta-analysis investigating the efﬁcacy of NSAIDs vs placebo
in patients with knee OA found a higher effect size (0.32) for studiesublished by Elsevier Ltd. All rights reserved.
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a ﬂare design (effect size 0.23)12. Vlad et al. examined differences in
study characteristics among glucosamine trials in OA; they found
consistently higher effect sizes in trials with industry funding (0.47)
vs trials without industry funding (0.05)13. Furthermore, one
randomized controlled trial (RCT) reported that NSAIDs are supe-
rior in patients with moderate to severe pain, but in patients with
mild intensity pain the differences between NSAIDs and acet-
aminophen were negligible14. Bradley et al., reported that higher
baseline pain intensity predicted greater pain relief at follow-up15.
The present review assesses the presence of statistical, meth-
odological and clinical heterogeneity of RCTs comparing NSAIDs vs
acetaminophen in knee and hip OA, with the aim to elucidate
variations in outcomes.Methods
Prisma recommendations
When executing the review the recommendations of the
Preferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA)16 were followed.Protocol
Methods of the data-analysis and selection criteria were speci-
ﬁed in advance and documented in a protocol (not published).Search strategy
A search (1966 to January 2010) of PubMed, Embase, Web of
Science, Cinahl, Scopus, and the Cochrane Library (Cochrane data-
base of systematic reviews, database of abstracts of reviews of
effects, and Cochrane central register of controlled trials) was
performed to identify studies evaluating the effectiveness of
NSAIDs vs acetaminophen in OA. The databases were searched
using the following terms: “Non-steroidal anti-inﬂammatory
agent”, “Paracetamol”, “Acetaminophen”, and “OA”. A detailed
description of the full electronic search strategies is provided in
Appendix A.Selection criteria
Inclusion criteria
All RCTs, controlled clinical trials (CCTs), and quasi-RCTs (qRCTs)
comparing NSAIDs and acetaminophen in OA patients aged 18
years and older were included. Trials with a cross-over designwere
also eligible. OA was either determined clinically and/or with
radiography. Studies in the English, German, or Dutch language
were included.
Exclusion criteria
Studies were excluded if they did not pertain to OA or concerned
non-oral pharmacologic therapy.Study collection
Two authors (SV and PL) independently evaluated all eligible
titles, abstracts, and full-text articles based on the inclusion and
exclusion criteria. Disagreement was resolved by discussion. From
relevant articles the references lists were searched for additional
articles.Data extraction
One author (SV) performed the data extraction using a stan-
dardized form. In case of uncertainty a second author was
consulted. The following data were collected:
(1) Demographic and clinical characteristics at baseline (age,
baseline pain intensity, previous used medication, mean duration
of complaints due to OA, radiographic severity, and patient pref-
erences); (2) outcomes at follow-up (mean difference and standard
deviations (SD) in pain, use of rescue medication, co-interventions,
and loss to follow-up); and (3) design characteristics (ﬂare design,
localisation of OA, dosage of NSAID and acetaminophen, duration of
follow-up in weeks, sample size, criteria for eligible patients,
setting and recruitment, and industry funding).
Methodological quality of the studies
The methodological quality of the included studies was inde-
pendently assessed by two authors (SV and PL, BK, AB, or SB) using
a predeﬁned list by the Cochrane Collaboration17, which is based on
the Delphi criteria18. Dissimilarity between researchers was
resolved by discussion. Scored items were: (1) randomization
procedure (randomization generation and randomization
concealment), (2) blinding (participants, care provider, and
outcome assessors), (3) incomplete outcome data (drop-out rates
and number of participants analysed in the group of allocation), (4)
selective outcome reporting, and (5) other sources of bias related to
comparability of study groups at baseline, co-interventions,
compliance to treatment, and timing of outcome assessment.
Each item was rated as ‘Yes’ (indicating a low risk of bias), ‘No’
(indicating a high risk of bias), or ‘Unclear’ (indicating unclear or
unknown risk of bias).
Types of outcome measures
Pain intensity was used as the main outcome measure, which
was assessed by standardized and validated scales or question-
naires, such as the Western Ontario and McMaster Osteoarthritis
index (WOMAC)19 or the visual analog scale (VAS). If WOMAC or
VAS datawere not available, othermeasures of painwere used (e.g.,
pain at rest, pain during walking, etc.). If possible, all scales and
questionnaires were converted to a standardized scale from 0 to
100 (0¼ no pain; 100¼worst pain ever). In addition, standardized
mean differences (SMD) of pain were used to measure the magni-
tude of the treatment effect (with negative values in favor of
NSAIDs). According to Cohen, a treatment effect of 0.2e0.5 is
regarded as a small effect, 0.5e0.8 is a medium effect, and a score of
0.8 or higher a large treatment effect20. If data on the primary
outcome were missing, authors of the included studies were
contacted.
Data analyses
Extracted data on number of patients, mean differences in pain
intensity, and SD were used to estimate the pooled SMD. If SDs
were not reported, they were obtained from conﬁdence intervals or
standard errors. If necessary, authors of the speciﬁc study were
asked for more information. Otherwise, baseline SDs were used or
imputations were made using SDs from a similar study. Regarding
cross-over design, only data of the ﬁrst comparison before crossing-
over were included for analysis.
If eligible studies compared different types or multiple dosages
of NSAIDs to acetaminophen, all types and dosages were included
in the analyses as separate comparisons. To avoid double counting
of the acetaminophen group, the number of participants in the
acetaminophen group was divided by the number of comparisons
of NSAIDs.
Fig. 1. Flowchart of the study selection.
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tical test to indicate the extent of heterogeneity is the Cochran’s
Q-test. However, this test has relatively low power to detect
heterogeneity when meta-analysis includes a small number of
studies. Therefore, the degree of heterogeneity was quantiﬁed with
the method of Higgins et al.21,22. With the method of Higgins et al.,
the variation across a study caused by heterogeneity and not by
chance is measured with I2. I2 is calculated with the Cochran’s
Q-test and the degrees of freedom. I2 values range from 0% to 100%:
an I2 of 0% indicates no observed heterogeneity, and 25%, 50%, and
75% indicate low, moderate, and high heterogeneity, respectively.
An I2 of 50% means that half of the total variability among effect
sizes is not caused by sampling error, but by true heterogeneity
between studies21. Besides using I2, the extent of heterogeneity was
also assessed by exploring the changes in SMD.
We hypothesized that the following trial characteristics might
inﬂuence the results: baseline pain intensity, ﬂare design, use of
previous pain medication, radiographic severity, localisation of OA,
methodological quality, duration of follow-up, sample size, dosage
of acetaminophen, types and dosage of NSAID, and industry
funding.
To assess the possibility of publication bias we evaluated a fun-
nel plot visually for symmetry.
Baseline pain intensity was categorized as ‘moderate’ (55 on
a scale of 0e100) vs ‘high’ (>55). Dosage of NSAID was catego-
rized, based on the Dutch information leaﬂet, as ‘normal’ for
ibuprofen 1200 mg, rofecoxib 12.5 mg, naproxen 440 and 660 mg,
and ﬂoctafenin 800 mg. Dosage of NSAID was categorized as ‘high’
for ibuprofen 2400 mg, diclofenac 150 mg, rofecoxib 25 mg, ace-
clofenac 200 mg, celecoxib 200 mg, and naproxen 750 mg. Types
of NSAIDs were categorized as cyclo-oxygenase-2 inhibitors
(rofecoxib and celecoxib), phenylacetic acids (diclofenac and
aceclofenac), or propanoic-phenolic acids (ibuprofen and nap-
roxen). Dosage of acetaminophen was categorized as ‘low’
(<3000 mg) or ‘high’ (3000 mg). Industry funding was catego-
rized as ‘absent’ (no reports of industry funding were reported in
the study) and ‘present’. Duration of follow-up was deﬁned as
‘short follow-up’ (<6 weeks) or ‘long follow-up’ (6 weeks).
Sample size was divided into ‘small’ (<100 patients) and ‘large’
(>100 patients).
We used both ﬁxed-effect and random-effect models to
analyse the results. If both models presented the results equally,
only the results of the ﬁxed-effect model are presented. Review
manager 5.0 and STATA 11 (StataCorp. 2009. Stata Statistical
Software: Release 11. College Station, TX: StataCorp LP) were used
for the analyses.
Results
The literature search yielded 1659 potentially eligible studies.
Finally, 14 articles were included in the present review (Fig. 1)23e36.
One article published data from two separate studies30. Four
studies had more than one comparison (range 2e3)25,27,32,33. In
total, 15 studies and 21 comparisons were included in the present
review.
Study characteristics
Table I presents the characteristics of the included studies. Both
ﬁxed-effect and random-effect models yielded the same results, so
we presented the results of the ﬁxed-effect analysis only. A total of
5133 patients were randomized, of whom 3275 received an NSAID
and 1858 received acetaminophen. All studies were RCTs. Three
studies had a cross-over design14,29,30. All studies included patients
with knee OA. Six studies also included patients with hipOA24,29e31,35. Seven different NSAIDs (naproxen, celecoxib, rofe-
coxib, ﬂoctafenin, ibuprofen, diclofenac, and aceclofenac) were
compared to acetaminophen. With the exception of one study36, all
studies used a wash-out period prior to randomization. Three
studies also required a ﬂare of symptoms after the wash-out
period32,33,35. Industry funding was reported in 11 of the 15 stud-
ies23,24,27,28,30e35. All studies reported hip or knee pain intensity as
a primary outcome for effectiveness of NSAID vs acetaminophen.
Pain intensity was measured by the WOMAC pain scale,
a 0e100 mm VAS, or a 4/5-point numerical scale (pain at rest). The
mean duration of follow-up was 15.4 (range 1e104) weeks.
Table II presents the risk of bias assessment. With the exception
of one study34, all studies were blinded. The procedure of random-
ization generation, randomization concealment, and blinding was
satisfactorily reported in only four studies23,29,35,36.
Effectiveness of NSAID vs acetaminophen
A total of 14 studies and 20 comparisons provided analyzable
data of 2991 patients in the NSAID group vs 1561 patients in the
acetaminophen group. The pooled SMDwas0.29 [95% conﬁdence
interval (95% CI): 0.35 to 0.22], referring to a small treatment
effect in favor of NSAIDs (Fig. 2). This ﬁnding is in accordance with
results from previous reviews5e8.
Heterogeneity
Statistical heterogeneity
No statistical heterogeneity was found between the included
comparisons evaluating NSAIDs vs acetaminophen in knee and hip
OA (Cochran’s Q-test¼ 14.11; I2¼ 0; P¼ 0.78) (Fig. 2).
Table I
Characteristics of studies evaluating the effectiveness of NSAIDs vs acetaminophen in patients with knee and hip OA
Study n Joints (%) Mean age (years) NSAID and dosage
(mg/day)
Acet# dosage
(mg/day)
Baseline pain
NSAID
Baseline pain
Acet
Duration
(weeks)
Flare design Industry
involvement
Battle-Gualda et al.23 168 Knee 62.4 Aceclofenac 200 3000 62.2{ 62.4{ 6 Wash out Yes
Boureau et al.24 222 Hip (29.5) 66.5 Ibuprofen 1200 3000 71.3y 72.2y 2 Wash out Yes
Knee (70.5)
Bradley et al.25 184 Knee 56.5 Ibuprofen 1200 4000 50x 54x 4 Wash out No
Ibuprofen 2400 49x
Case et al.26 54 Knee 62.5 Diclofenac 150 4000 37y 31.8y 12 Wash out No
Geba et al.27 382 Knee 62.6 Celecoxib 200 4000 Unknowny Unknowny 6 Wash out Yes
Rofecoxib 12.5
Rofecoxib 25
Golden et al.28 310 Knee 60.7 Naproxen 440/660 4000 35.3x 34.5x 1 Wash out Yes
Lequesne et al.29,y 192 Hip (33.5) 64.7 Floctafenin 800 3000 64.5{ 60.9{ 1.7 Wash out No
Knee (66.5)
Pincus et al.14,y 227 Hip (22) 61.5 Diclofenac 150 4000 40.2y 42.1y 9 Wash out Yes
Knee (78)
Pincus et al.30,y 235 Hip (16.4) 63.5 Celecoxib 200 4000 48.6y 52.8y 6 Wash out Yes
Knee (83.6)
250 Hip (15.5) 63.7 Celecoxib 200 4000 52y 51.6y 6 Wash out Yes
Knee (84.5)
Schnitzer et al.33 1578 Knee 62.1 Celecoxib 200 4000 Unknowny Unknowny 6 Yes Yes
Rofecoxib 12.5
Rofecoxib 25
Schnitzer et al.32 403 Knee 59.8z Rofecoxib 12.5 1300 57.2y 58.1y 4 Yes Yes
Rofecoxib 25 62.1y
Shen et al.34 20 Knee Unknown Rofecoxib 25 4000 68.5y 90.5y 12 Wash out Yes
Temple et al.35 571 Hip/knee 59.3 Naproxen 750 4000 Unknown Unknown 52 Yes Yes
Williams et al.36 178 Knee 59.6 Naproxen 750 2600 26x 29x 104* No No
* Intention to treat analysis after 42 days.
y Cross-over design.
z Characteristics of the intention to treat analysis.
x Rest pain measured on a four-point or a ﬁve-point scale.
y Pain measured with the WOMAC.
{ Pain measured with a VAS.
# Acet: acetaminophen.
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Subgroup analysis (Table III) showed no differences in effect
between comparisonswith andwithout a ﬂare design (SMD:0.27;
95% CI: 0.39 to 0.16 vs 0.30; 0.38 to 0.21), between
comparison that were inadequately blinded (032;0.60 to0.04)
vs adequately blinded comparisons (0.29; 0.35 to 0.22),
comparisons that adequately addressed with incomplete outcome
data (0.28; 0.35 to 0.21) vs comparisons that inadequately
addressed incomplete outcome data (0.32; 0.47 to 0.17), and
comparisons that adequately addressed other sources of bias
(0.28; 0.45 to 0.11) vs comparisons that did not address other
sources of bias adequately (0.29; 0.36 to 0.22).
Comparisons without industry funding have a somewhat higher
treatment effect in favor of NSAIDs vs comparisons with industry
funding (0.40; 0.59 to 0.22 vs 0.30; 0.38 to 0.21). The
same was found for comparisons with an adequate randomization
procedure (0.39; 0.57 to 0.21) vs uncertainty in the randomi-
zation procedure (0.27; 0.34 to 0.20), comparisons with
a sample size of 100 patients (0.35; 0.46 to 0.23) vs
comparisons with a sample size of 100 patients (0.27; 0.34
to 0.19), and for comparisons with a short follow-up (0.35;
0.46 to 0.23) vs long follow-up (0.26; 0.34 to 0.18).
Comparisons with a short follow-up showedminor methodological
heterogeneity (I2¼19%). None of these differences were of clinical
or statistical signiﬁcance (Table III).
Clinical heterogeneity
Comparisons which included patients with hip and knee OA
showed moderate clinical heterogeneity (I2¼ 51%; P¼ 0.09)
(Table III). Therewas a small trend for a better effectiveness ofNSAIDs
compared with acetaminophen in studies which included a higher
percentage of patients with hip OA. However, the pooled effect sizes
of the comparisons with knee OA only vs knee and hip OA are the
same(Fig.2). Comparisonswithmoderatebaselinepain intensity, low
dosage of acetaminophen, andnormaldosage ofNSAIDs showedonly
low clinical heterogeneity (I2 of 19%, 21%, and 26%, respectively).
Subgroupanalysis (Table III) showed thatcomparisonswithmoderate
pain intensity at baseline have a slightly higher treatment effect in
favor of NSAIDs than comparisons with high pain at baseline
(SMD: 0.37; 95% CI: 0.51 to 0.24 vs 0.25; 0.35 to 0.16). The
samewas found forcomparisonswitha lowdosageofacetaminophen
(0.36; 0.49 to 0.24) vs a high dosage of acetaminophen (0.26;
0.34 to0.18), comparisonswithanormaldosageofNSAIDs (0.32;
0.43 to0.20)vshighdosageofNSAIDs(0.27;0.35 to0.19), and
for comparisons of propanoic-phenolic acids (0.35;0.48 to0.21)
vs phenylacetic acids and coxibs (0.31; 0.49 to 0.12
and 0.24;0.33 to 0.16, respectively).
Publication bias
Based on the funnel plot, there appears to be no indication for
publication bias (Fig. 3).
Discussion
This systematic review investigated various sources of hetero-
geneity (statistical, clinical, and methodological) of RCTs evaluating
the effectiveness of acetaminophen vs NSAIDs in patients with knee
and hip OA in relation to pain outcomes. We found moderate
clinical heterogeneity for the ﬁve studies that included both hip
and knee OA14,24,29,30,35. Unfortunately, data on knee and hip OA
were not presented separately in the available studies. Our forest
plot showed a higher effect size in favor of NSAIDs in studies that
included a higher percentage of patients with hip OA. Svensson
et al. also found differences in effectiveness in patients with hip and
knee OA treated with naproxen. Yet, they found a greater
Fig. 2. Forest plot of SMD for pain improvement in NSAIDs vs acetaminophen stratiﬁed by location of OA.
S.P.J. Verkleij et al. / Osteoarthritis and Cartilage 19 (2011) 921e929926improvement in patients with knee OA compared with hip OA37.
Future research should stratify the results of hip and knee OA.
Furthermore, our review showed low but non-signiﬁcant clinical
and methodological heterogeneity for comparisons evaluating low
dosage of acetaminophen, normal dosage of NSAIDs, moderate pain
intensity at baseline, and follow-up of 6 weeks.
Pincus et al. reported that efﬁcacy of NSAIDs and acetaminophen
is probably the same in patients with mild OA14. Our subgroup
analyses showed a higher effect size in trials with moderate pain
intensity at baseline compared to trials with high pain at baseline;
however, the differences were small and therefore not important.
In contrast toVlad et al.13 ourheterogeneityanalyses showed that
studies without industry funding have a slightly higher but non-
signiﬁcant effect size compared with studies with industry fund-
ing (SMD:0.40; 95% CI:0.59 to0.22 vs0.30;0.38 to0.21).
Thisﬁnding is in accordancewith Lee et al.6 In apost hoc stratiﬁcation
we looked more deeply for inﬂuences of industry funding. We
stratiﬁed funded studies according to their SMD. Studies that were
signiﬁcantly in favor of NSAIDs showed no heterogeneity but, not
surprisingly, showed a higher overall SMD (0.33; 0.42 to 0.24)
in favor of NSAIDs compared to those studies that were not signiﬁ-
cantly in favor of NSAIDs (0.14; 0.26 to 0.02).
Except for one study36, all included studies used a pre-treatment
wash-out period before randomization. Additionally, three studies
also required a ﬂare of symptoms after medication discontinuation,
before the start of the study32,33,35. The study of Scott-Lennox et al.
examined the impact of ﬂare designs on trial results and reported
a more profound pain reduction in patients with an intense ﬂare
prior to treatment38.
Four of the included studies compared rofecoxib (Vioxx) with
acetaminophen27,32e34, whereas rofecoxibwaswithdrawn from themarket in 2004. We have included these studies in the present
review because we were interested in the heterogeneity of studies
evaluating the effect of NSAIDs vs acetaminophen on pain control.
However, additional analysis showed that the exclusion of the
rofecoxib trials did not alter the results (data not shown).
Similar to Bjordal et al.12, we found that mean age of the
participants was relatively low (61.6 years; SD 2.46) for patients
with OA. Three studies excluded participants above 75 years of
age23,26,35 and one study excluded patients aged 85 years and
older24. Although, prescribing NSAIDs in older adults is not without
risks39, the exclusion of these patients could cause selection bias.
Therefore, future studies should not exclude older patients but
carefully screen them before inclusion and monitor them after
inclusion.
In line with previous reviews5e8, we found a signiﬁcant
improvement in pain in favor of NSAIDs in patients with knee and/
or hip OA. We included three additional studies23,32,35 that were
published since the last review appeared in 20065.
The effectiveness of acetaminophen vs NSAIDs is an important
question in all guidelines for OA. It is striking, that there is a relative
lack of good quality randomized studies that evaluate the effec-
tiveness of acetaminophen vs NSAIDs. Therefore, high quality
research is needed to substantiate the effectiveness of NSAIDs over
acetaminophen.
Limitations
The present review has some limitations. First, although no
publication bias was revealed (Fig. 3), we cannot be certain that all
published/unpublished studies were retrieved. Secondly, four
studies includedmore than one comparison of NSAIDs25,27,32,33. We
Table III
Pooled effect estimates of clinical and methodological heterogeneity
Number of
studies/
comparisons
SMD (95% CI) I2
All studies 14/20 0.29 (0.35 to 0.22) 0
Methodological characteristics
Flare design
Present 2/5 0.27 (0.39 to 0.16) 0
Absent 12/15 0.30 (0.38 to 0.22) 0
Industry funding*
Present 10 studies 0.30 (0.38 to 0.21) 0
Absent 4 studies 0.40 (0.59 to 0.22) 0
Randomization procedure
Adequate 3/3 0.39 (0.57 to 0.21) 0
No/unsure 11/17 0.27 (0.34 to 0.20) 0
Blinding
Adequate 12/18 0.29 (0.35 to 0.22) 0
No/unsure 2/2 0.32 (0.60 to 0.04) 0
Incomplete outcome data
Adequate 10/16 0.28 (0.35 to 0.21) 0
No/unsure 4/4 0.32 (0.47 to 0.17) 0
Bias
Adequate 3/3 0.28 (0.45 to 0.11) 0
No/unsure 11/17 0.29 (0.36 to 0.22) 0
Sample size
<100 in NSAID group 7/10 0.35 (0.47 to 0.23) 0
>100 in NSAID group 7/10 0.27 (0.34 to 0.19) 0
Duration of follow-up
<6 Weeks 5/7 0.35 (0.46 to 0.23) 19%
6 Weeks 9/13 0.26 (0.34 to 0.18) 0
Clinical characteristics
Localisation of OA
Knee 9/15 028 (0.36 to 0.20) 0
Knee and hip 5/5 0.30 (0.41 to 0.19) 51%
Baseline pain intensity*
Moderate 7/8 0.37 (0.51 to 0.24) 19%
High 5/6 0.25 (0.35 to 0.16) 0
Missing 2/6
Dosage of acetaminopheny
Low 2/3 0.36 (0.49 to 0.24) 21%
High 12/17 0.26 (0.34 to 0.18) 0
Dosage of NSAIDz
Normal 7 comparisons 0.32 (0.43 to 0.20) 26%
High 13 comparisons 0.27 (0.35 to 0.19) 0
Type of NSAIDx
Coxib 6/11 0.24 (0.33 to 0.16) 0
Phenylacetic acids 3/3 0.31 (0.49 to 0.12) 0
Propanoic-phenolic acids 4/5 0.35 (0.48 to 0.21) 0
Other 1/1
Bold¼ P< 0.10.
I2¼measure of heterogeneity; SMD (negative values are in favor of NSAIDs).
* With multi-group studies, only the highest dosage was included for analysis.
y Medication acetaminophen: low 2600 mg.
z Medication NSAID: normal: ibuprofen 1200 mg, rofecoxib 12.5 mg, naproxen
440/660 mg, and ﬂoctafenin 800 mg; medication NSAID high: ibuprofen 2400 mg,
diclofenac 150 mg, rofecoxib 25 mg, naproxen 750 mg, aceclofenac 200 mg, and
celecoxib 200 mg.
x Cyclo-oxygenase-2 inhibitors (coxibs) are rofecoxib and celecoxib; phenylacetic
acids are diclofenac and aceclofenac; propanoic-phenolic acids are ibuprofen and
naproxen; other: ﬂoctafenin.
* High baseline pain was deﬁned as a pain score of 55 or higher on a scale of
0e100; moderate pain intensity was a pain score of 55 or lower.
Fig. 3. Funnel plot for publication bias.
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participants of the acetaminophen group by the number of
comparisons of NSAIDs which could have biased the results,
possibly leading to an underestimation. Thirdly, one of our aims
was to examine relevant trial characteristics that may cause
heterogeneity. However, not all clinical features were always
reported satisfactorily. For example, data on the use of previous
pain medication was only reported satisfactorily in four trials
(which included nine comparisons)26,27,30,33, the mean duration of
complaints was reported in four trials (which included ﬁve
comparisons)23,24,30,36, and radiographic severity was only repor-
ted in ﬁve trials (which included six comparisons)14,23,26,30,36. These
characteristics may have inﬂuenced the reported results. Moreover,
Case et al. reported that prior use of NSAIDs predicted a better
response of NSAIDs compared to acetaminophen26.
Another limitation is that, due to the small numbers we per-
formed subgroup analysis with only one study characteristic (uni-
variable analysis). Based on univariable analyses it is impossible to
draw broad conclusion. Furthermore, it was not possible to study
interaction effects of the treatment in subgroups of patients.
Therefore, future meta-analyses should focus on individual patient
data (IPD). The use of IPD in meta-analyses has been described as
the gold standard40, allowing to assess the existence of heteroge-
neity more reliably. Furthermore, IPD can be used to investigate
speciﬁc treatment effects in various subgroups41.
Conclusion
In conclusion, future trials should present the results of patients
with hip and knee OA separately, as we found moderate hetero-
geneity in trials that included patients with both knee and hip OA.
Furthermore, no clinically relevant statistical, methodological, or
clinical heterogeneity was found for studies evaluating the effec-
tiveness of NSAIDs vs acetaminophen in knee and hip OA.
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Appendix A
Medical Subject Headings and text word search strategies performed in Embase,
Cinahl, Cochrane Library, Scopus, PubMed, and Web of Science (1966 to January
2010)
Embase/Cinahl/Cochrane
Library/Scopus
PubMed/Web of Science
1. Non-steroidal anti-inﬂammatory
agent/syn*
1. Anti-inﬂammatory agents,
Non-steroidal[mesh]
2. Paracetamol/syn*z 2. NSAIDs[tw]
3. Acetaminophen 3. Non-steroidal anti-inﬂammatory
agents[tw]
4. OA/syn* 4. Non-steroidal anti-inﬂammatory
agents[tw]
5. Controlled clinical trial/limyz 5. Non-steroidal anti-inﬂammatory
agents[tw]
6. RCT/limyz 6. Non-steroidal anti-inﬂammatory
agents[tw]
7. Adult/limyz 7. Non-steroidal anti-inﬂammatory
agents[tw]
8. Aged/limyz 8. Non-steroidal antirheumatic
agents[tw]
9. Titleeabstractekeywordx 9. Aspirin-like agents[tw]
10. Aspirin-like agents[tw]
11. Analgesics, anti-inﬂammatory[tw]
12. Analgesics, anti-inﬂammatory[tw]
13. Anti-inﬂammatory analgesics[tw]
14. OR 1e13
15. Acetaminophen[mesh]
16. Acetaminophen[tw]
17. Hydroxyacetanilide[tw]
18. APAP[tw]
19. N-acetyl-p-aminophenol[tw]
20. p-Acetamidophenol[tw]
21. p-Hydroxyacetanilide[tw]
22. Paracetamol[tw]
23. Acetamidophenol[tw]
24. Acephen[tw]
25. Tylenol[tw]
26. Panadol[tw]
27. Acamol[tw]
28. OR 15e27
29. OA[mesh]
30. OA[tw]
31. Osteoarthrosis[tw]
32. OR 29e31
mesh¼Medical subject heading; tw¼ text word.
* syn¼ Synonym. The term synonym is only used in Embase.
y lim¼ Limitation.
z Search strategy only used in Embase.
x Search strategy only used in Scopus.
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